PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Linda Vidarsdottir, Alireza Azimi, Ishani Das, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, Rainer Tuominen, Olle Sangfelt, Katja Pokrovskaja Tamm, Johan Hansson, Dan Grandér, Suzanne Egyházi Brage, Per Johnsson

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)

Abstract BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy.

Externí odkaz: https://doaj.org/article/f88ae22862f24b9684552bdca23e8edf

Supplementary Table 3 from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer

Autor: Ingrid Hedenfalk, Thomas Hatschek, Mårten Fernö, Thomas M. Walz, Martin Söderberg, Per-Olof Malmström, Niklas Loman, Barbro Linderholm, Elisabet Lidbrink, Zakaria Einbeigi, Lena Carlsson, Lambert Skoog, Marianne Frostvik Stolt, Suzanne Egyhazi Brage, Srinivas Veerla, Anna Danielsson, Ida Johansson, Siker Kimbung

Gene ontology analysis showing significantly enriched GO-terms for biological process among the significantly altered genes in breast cancer liver metastases compared to metastases from other sites.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3b38291e98dcb4c049cac8d51d74590
https://doi.org/10.1158/1078-0432.22460037

Data from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer

Autor: Ingrid Hedenfalk, Thomas Hatschek, Mårten Fernö, Thomas M. Walz, Martin Söderberg, Per-Olof Malmström, Niklas Loman, Barbro Linderholm, Elisabet Lidbrink, Zakaria Einbeigi, Lena Carlsson, Lambert Skoog, Marianne Frostvik Stolt, Suzanne Egyhazi Brage, Srinivas Veerla, Anna Danielsson, Ida Johansson, Siker Kimbung

Purpose: The complete molecular basis of the organ-specificity of metastasis is elusive. This study aimed to provide an independent characterization of the transcriptional landscape of breast cancer metastases with the specific objective to identify

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78cea53a481eab204813314df3fe5f86
https://doi.org/10.1158/1078-0432.c.6524385

Supplementary table 4 from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer

Autor: Ingrid Hedenfalk, Thomas Hatschek, Mårten Fernö, Thomas M. Walz, Martin Söderberg, Per-Olof Malmström, Niklas Loman, Barbro Linderholm, Elisabet Lidbrink, Zakaria Einbeigi, Lena Carlsson, Lambert Skoog, Marianne Frostvik Stolt, Suzanne Egyhazi Brage, Srinivas Veerla, Anna Danielsson, Ida Johansson, Siker Kimbung

Multivariable Cox proportional hazards analyses for relapse-free survival (RFS) and overall survival (OS) among patients with ER positive primary tumors in GOBO. Separate analyses are shown for all ER positive tumors and the subset of luminal A tumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5571a4838cbe576a0474285b6e88e5e3
https://doi.org/10.1158/1078-0432.22460034

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Marianne Frostvik Stolt, Rainer Tuominen, Dan Grandér, Ishani Das, Per Johnsson, Aldwin Suryo Rahmanto, Johan Hansson, Håkan Olsson, Göran Jönsson, Sakari Kauppinen, Alireza Azimi, Christian Ingvar, Linda Vidarsdottir, Ingibjorg Sigvaldadottir, Andreas Petri, Olle Sangfelt, Katja Pokrovskaja Tamm, Suzanne Egyhazi Brage

Publikováno v: Vidarsdottir, L, Azimi, A, Das, I, Sigvaldadottir, I, Suryo Rahmanto, A, Petri, A, Kauppinen, S, Ingvar, C, Jönsson, G, Olsson, H, Frostvik Stolt, M, Tuominen, R, Sangfelt, O, Pokrovskaja Tamm, K, Hansson, J, Grandér, D, Egyházi Brage, S & Johnsson, P 2021, ' PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma ', Scientific Reports, vol. 11, no. 1, 11023 . https://doi.org/10.1038/s41598-021-89389-9
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports

BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450435b6413ba470b4e369e6f91f03c9
https://vbn.aau.dk/da/publications/4126c388-b76b-418b-bab9-cd4b3824935b